卒中：回眸2023

doi:10.3969/j.issn.1673-5765.2024.01.001

摘要/Abstract

摘要： 在全球脑血管病医疗工作者的共同努力下，近年来脑血管病的诊疗取得了长足的进步。众多高质量的临床研究涵盖了脑血管病多个领域和热点，例如：缺血性卒中急性期取栓/溶栓，针对心房颤动的干预，血压管理等其他卒中急性期干预措施，为脑血管病的临床诊疗提供了扎实可靠的循证医学证据，并促进了脑血管病疾病负担的降低。本文对2023年脑血管病领域重要的临床研究进展进行回顾，帮助读者更好地了解这些临床研究的精华，并期待未来涌现出更多、更好的脑血管病临床研究。

关键词: 卒中; 脑血管病; 再灌注; 血管内治疗; 静脉溶栓; 心房颤动; 二级预防

Abstract: Cerebrovascular clinicians from different countries all over the world made great progress in the diagnosis and treatment of cerebral vascular diseases in recent years. Numerous high-quality clinical studies cover multiple fields and hotspots of cerebral vascular disease, such as thrombectomy/thrombolysis in the acute phase of ischemic stroke, intervention for atrial fibrillation, blood pressure management and other acute phase intervention measures, providing solid and reliable evidence-based medical evidence for clinical diagnosis and treatment in cerebral vascular disease, and promoting the reduction of cerebral vascular disease burden. This paper reviews the important clinical research progress in the field of cerebral vascular disease in 2023, helping readers better understand the advantages and great significance of these clinical studies, and looking forward to more and better cerebral vascular disease clinical studies in the future.

Key words: Stroke; Cerebralvascular disease; Reperfusion; Endovascular treatment; Intravenous thrombolysis; Atrial fibrillation; Secondary prevention

中图分类号:

王拥军, 熊云云, 李光硕, 曹智鑫, 王文洁, 闫然, 王利圆, 路正钊, 郝曼均. 卒中：回眸2023[J]. 中国卒中杂志, 2024, 19(1): 1-21.

WANG Yongjun, XIONG Yunyun, LI Guangshuo, CAO Zhixin, WANG Wenjie, YAN Ran, WANG Liyuan, LU Zhengzhao, HAO Manjun. Highlights in Stroke in 2023[J]. Chinese Journal of Stroke, 2024, 19(1): 1-21.

参考文献

[1] HEALEY J S，CONNOLLY S J，GOLD M R，et al. Subclinical atrial fibrillation and the risk of stroke[J]. N Engl J Med，2012，366（2）：120-129.
[2] GLOTZER T V，HELLKAMP A S，ZIMMERMAN J，et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke：report of the atrial diagnostics ancillary study of the mode selection trial（MOST）[J]. Circulation，2003，107（12）：1614-1619.
[3] CONNOLLY S J，EIKELBOOM J，JOYNER C，et al. Apixaban in patients with atrial fibrillation[J]. N Engl J Med，2011，364（9）：806-817.
[4] RUFF C T，GIUGLIANO R P，BRAUNWALD E，et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation：a meta-analysis of randomised trials[J]. Lancet，2014，383（9921）：955-962.
[5] KIRCHHOF P，TOENNIS T，GOETTE A，et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes[J]. N Engl J Med，2023，389（13）：1167-1179.
[6] KAATZ S，AHMAD D，SPYROPOULOS A C，et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients：communication from the SSC of the ISTH[J]. J Thromb Haemost，2015，13（11）：2119-2126.
[7] HEALEY J S，LOPES R D，GRANGER C B，et al. Apixaban for stroke prevention in subclinical atrial fibrillation[J]. N Engl J Med，2024，390（2）：107-117.
[8] SVENNBERG E. What lies beneath the surface-treatment of subclinical atrial fibrillation[J]. N Engl J Med，2024，390（2）：175-177.
[9] 刘丽萍，周宏宇，段婉莹，等. 中国脑血管病临床管理指南（第2版）（节选）——第4章缺血性脑血管病临床管理推荐意见[J]. 中国卒中杂志，2023，18（8）：910-933.
LIU L P，ZHOU H Y，DUAN W Y，et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）—chapter four clinical management of ischaemic cerebrovascular diseases[J]. Chin J Stroke，2023，18（8）：910-933.
[10] SAQQUR M，UCHINO K，DEMCHUK A M，et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke[J]. Stroke，2007，38（3）：948-954.
[11] de SILVA D A，BREKENFELD C，EBINGER M，et al. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the echoplanar imaging thrombolytic evaluation trial（EPITHET）[J]. Stroke，2010，41（2）：295-299.
[12] van de WERF F，ADGEY J，ARDISSINO D，et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction：the ASSENT-2 double-blind randomised trial[J]. Lancet，1999，354（9180）：716-722.
[13] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[14] LI S Y，PAN Y S，WANG Z R，et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke（TRACE）：a multicentre，randomised，open label，blinded-endpoint（PROBE）controlled phaseⅡstudy[J]. Stroke Vascul Neurol，2022，7（1）：47-53.
[15] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[16] MENON B K，SINGH N，SYLAJA P N. Tenecteplase use in patients with acute ischaemic stroke[J]. Lancet，2023，401（10377）：618-619.
[17] 郝曼均，曹智鑫，李光硕，等. 英国国家卒中临床指南2023版要点及解读——缺血性卒中[J]. 中国卒中杂志，2023，18（12）：1357-1364.
HAO M J，CAO Z X，LI G S，et al. Interpretation of the updates on national clinical guideline for stroke for the United Kingdom and Ireland—ischemic stroke[J]. Chin J Stroke，2023，18（12）：1357-1364.
[18] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[19] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs. intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[20] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs. with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.
[21] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.
[22] FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.
[23] MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.
[24] 王拥军，熊云云，杨佳蕾，等. 卒中：回眸2020[J]. 中国卒中杂志，2021，16（2）：101-118.
WANG Y J，XIONG Y Y，YANG J L，et al. Highlights on stroke research in 2020[J]. Chin J Stroke，2021，16（2）：101-118.
[25] 王拥军，熊云云，李子孝，等. 卒中：回眸2021[J]. 中国卒中杂志，2022，17（1）：1-20.
WANG Y J，XIONG Y Y，LI Z X，et al. Highlights on stroke research in 2021[J]. Chin J Stroke，2022，17（1）：1-20.
[26] 熊云云，霍晓川，贾白雪等. 卒中：回眸2022[J]. 中国卒中杂志，2023，18（1）：1-16.
XIONG Y Y，HUO X C，JIA B X，et al. Highlights in stroke in 2022[J]. Chin J Stroke，2023，18（1）：1-16.
[27] MAJOIE C B，CAVALCANTE F，GRALLA J，et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke：individual participant data meta-analysis of six randomised trials[J]. Lancet，2023，402（10406）：965-974.
[28] EMBERSON J，LEES K R，LYDEN P，et al. Effect of treatment delay，age，and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke：a meta-analysis of individual patient data from randomised trials[J]. Lancet，2014，384（9958）：1929-1935.
[29] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association
[J/OL]. Stroke，2019，50（12）：e344-e418[2023-12-20].
https://doi.org/10.1161/str.0000000000000211.
[30] BENDSZUS M，FIEHLER J，SUBTIL F，et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct：multicentre，open-label，randomised trial[J]. Lancet，2023，402（10414）：1753-1763.
[31] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[32] HUO X C，MA G T，TONG X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.
[33] SARRAJ A，HASSAN A E，ABRAHAM M G，et al. Trial of endovascular thrombectomy for large ischemic strokes[J]. N Engl J Med，2023，388（14）：1259-1271.
[34] FAYAD P. Improved prospects for thrombectomy in large ischemic stroke[J]. N Engl J Med，2023，388（14）：1326-1328.
[35] DIPPEL D W J，ROOZENBEEK B. Thrombectomy for acute ischaemic stroke without advanced imaging[J]. Lancet，2023，402（10414）：1724-1725.
[36] ALBERS G W，MARKS M P，KEMP S，et al. Thrombectomy for Stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med，2018，378（8）：708-718.
[37] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.
[38] BERKHEMER O A，FRANSEN P S，BEUMER D，et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med，2015，372（1）：11-20.
[39] BERKHEMER O A，JANSEN I G，BEUMER D，et al. Collateral status on baseline computed tomographic angiography and intra-arterial treatment effect in patients with proximal anterior circulation stroke[J]. Stroke，2016，47（3）：768-776.
[40] OLTHUIS S G H，PIRSON F A V，PINCKAERS F M E，et al. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography（MR CLEAN-LATE）in the Netherlands：a multicentre，open-label，blinded-endpoint，randomised，controlled，phase 3 trial[J]. Lancet，2023，401（10385）：1371-1380.
[41] WARDLAW J M. Even more benefit with endovascular treatment for patients with acute ischaemic stroke：MR CLEAN-LATE[J]. Lancet，2023，401（10385）：1317-1319.
[42] LI C W，ZHANG Y H，XU T，et al. Systolic blood pressure trajectories in the acute phase and clinical outcomes in 2-year follow-up among patients with ischemic strok[J]. Am J Hypertens，2019，32（3）：317-325.
[43] HE J，ZHANG Y H，XU T，et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke：the CATIS randomized clinical trial[J]. JAMA，2014，311（5）：479-489.
[44] XU T，ZHANG Y H，BU X Q，et al. Blood pressure reduction in acute ischemic stroke according to time to treatment：a subgroup analysis of the China antihypertensive trial in acute ischemic stroke trial[J]. J Hypertens，2017，35（6）：1244-1251.
[45] LIU L P，XIE X W，PAN Y S，et al. Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke：multicentre，open label，randomised，controlled trial[J/OL]. BMJ，2023，383：e076448[2023-12-23]. https://doi.org/10.1136/bmj-2023-076448.
[46] GOYAL N，TSIVGOULIS G，PANDHI A，et al. Blood pressure levels post mechanical thrombectomy and outcomes in large vessel occlusion strokes[J]. Neurology，2017，89（6）：540-547.
[47] HEO J H，HAN S W，LEE S K. Free radicals as triggers of brain edema formation after stroke[J]. Free Radic Biol Med，2005，39（1）：51-70.
[48] MARTINS A I，SARGENTO-FREITAS J，SILVA F，et al. Recanalization modulates association between blood pressure and functional outcome in acute ischemic stroke[J]. Stroke，2016，47（6）：1571-1576.
[49] MAZIGHI M，RICHARD S，LAPERGUE B，et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke（BP-TARGET）：a multicentre，open-label，randomised controlled trial[J]. Lancet Neurol，2021，20（4）：265-274.
[50] YANG P F，SONG L L，ZHANG Y W，et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke（ENCHANTED2/MT）：a multicentre，open-label，blinded-endpoint，randomised controlled trial[J]. Lancet，2022，400（10363）：1585-1596.
[51] NAM H S，KIM Y D，HEO J，et al. Intensive vs. conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke：the OPTIMAL-BP randomized clinical trial[J]. JAMA，2023，330（9）：832-842.
[52] MISTRY E A，HART K W，DAVIS L T，et al. Blood pressure management after endovascular therapy for acute ischemic stroke：the BEST-Ⅱ randomized clinical trial[J]. JAMA，2023，330（9）：821-831.
[53] SARRAJ A. Blood pressure management after successful thrombectomy[J]. JAMA，2023，330（9）：811-812.
[54] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[55] HEO J H，LEE K Y，KIM S H，et al. Immediate reocclusion following a successful thrombolysis in acute stroke：a pilot study[J]. Neurology，2003，60（10）：1684-1687.
[56] POWER S，MATOUK C，CASAUBON L K，et al. Vessel wall magnetic resonance imaging in acute ischemic stroke：effects of embolism and mechanical thrombectomy on the arterial wall[J]. Stroke，2014，45（8）：2330-2334.
[57] CANNON C P，WEINTRAUB W S，DEMOPOULOS L A，et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban[J]. N Engl J Med，2001，344（25）：1879-1887.
[58] Van’t HOF A W，TEN BERG J，HEESTERMANS T，et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty（On-TIME 2）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2008，372（9638）：537-546.
[59] KELLERT L，HAMETNER C，ROHDE S，et al. Endovascular stroke therapy：tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome[J]. Stroke，2013，44（5）：1453-1455.
[60] ZHAO W B，CHE R W，SHANG S Y，et al. Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy[J]. Stroke，2017，48（12）：3289-3294.
[61] RESCUE BT Trial Investigators，QIU Z M，LI F L，et al. Effect of intravenous tirofiban vs. placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke：the RESCUE BT randomized clinical trial[J]. JAMA，2022，328（6）：543-553.
[62] WU S M，WU B，LIU M，et al. Stroke in China：advances and challenges in epidemiology，prevention，and management[J]. Lancet Neurol，2019，18（4）：394-405.
[63] ZI W J，SONG J X，KONG W L，et al. Tirofiban for stroke without large or medium-sized vessel occlusion[J]. N Engl J Med，2023，388（22）：2025-2036.
[64] ALBERTS M J. In ischemic stroke without large or medium vessel occlusion，tirofiban increased likelihood of an excellent outcome[J/OL]. Ann Intern Med，2023，176（10）：JC111[2023-12-20]. https://doi.org/10.7326/j23-0074.
[65] ALEXANDROV A V，GROTTA J C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator[J]. Neurology，2002，59（6）：862-867.
[66] BARRETO A D，ALEXANDROV A V，LYDEN P，et al. The argatroban and tissue-type plasminogen activator stroke study：final results of a pilot safety study[J]. Stroke，2012，43（3）：770-775.
[67] LYDEN P，PEREIRA B，CHEN B，et al. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models[J]. Stroke，2014，45（3）：896-899.
[68] BARRETO A D，FORD G A，SHEN L，et al. Randomized，multicenter trial of ARTSS-2（argatroban with recombinant tissue plasminogen activator for acute stroke）[J]. Stroke，2017，48（6）：1608-1616.
[69] CHEN H S，CUI Y，ZHOU Z H，et al. Effect of argatroban plus intravenous alteplase vs. intravenous alteplase alone on neurologic function in patients with acute ischemic stroke：the ARAIS randomized clinical trial[J]. JAMA，2023，329（8）：640-650.
[70] SEIFFGE D J，WERRING D J，PACIARONI M，et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation[J]. Lancet Neurol，2019，18（1）：117-126.
[71] HEIDBUCHEL H，VERHAMME P，ALINGS M，et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation：executive summary[J]. Eur Heart J，2013，34（27）：2094-2106.
[72] FISCHER U，KOGA M，STRBIAN D，et al. Early versus later anticoagulation for stroke with atrial fibrillation[J]. N Engl J Med，2023，388（26）：2411-2421.
[73] UCHINO K. Anticoagulation conundrum in acute ischemic stroke with atrial fibrillation[J]. N Engl J Med，2023，388（26）：2479-2480.
[74] GRUBB R L Jr，DERDEYN C P，VIDEEN T O，et al. Relative mean transit time predicts subsequent stroke in symptomatic carotid occlusion[J]. J Stroke Cerebrovasc Dis，2016，25（6）：1421-1424.
[75] GRUBB R L Jr，DERDEYN C P，FRITSCH S M，et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion[J]. JAMA，1998，280（12）：1055-1060.
[76] KERN R，STEINKE W，DAFFERTSHOFER M，et al. Stroke recurrences in patients with symptomatic vs. asymptomatic middle cerebral artery disease[J]. Neurology，2005，65（6）：859-864.
[77] EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial[J]. N Engl J Med，1985，313（19）：1191-1200.
[78] POWERS W J，CLARKE W R，GRUBB R L，Jr，et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia：the carotid occlusion surgery study randomized trial[J]. JAMA，2011，306（18）：1983-1992.
[79] MA Y，WANG T，WANG H B，et al. Extracranial-intracranial bypass and risk of stroke and death in patients with symptomatic artery occlusion：the CMOSS randomized clinical trial[J]. JAMA，2023，330（8）：704-714.
[80] CHATURVEDI S，SIMARD J M. Extracranial-intracranial bypass surgery for stroke prevention[J]. JAMA，2023，330（8）：697-698.
[81] CORDONNIER C，DEMCHUK A，ZIAI W，et al. Intracerebral haemorrhage：current approaches to acute management[J]. Lancet，2018，392（10154）：1257-1268.
[82] MOULLAALI T J，WANG X，MARTIN R H，et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage：a preplanned pooled analysis of individual participant data[J]. Lancet Neurol，2019，18（9）：857-864.
[83] MOULLAALI T J，WANG X，SANDSET E C，et al. Early lowering of blood pressure after acute intracerebral haemorrhage：a systematic review and meta-analysis of individual patient data[J]. J Neurol Neurosurg Psychiatry，2022，93（1）：6-13.
[84] SANDSET E C，ANDERSON C S，BATH P M，et al. European Stroke Organisation（ESO）guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage[J/OL]. Eur Stroke J，2021，6（2）：Ⅱ[2023-12-20]. https://doi.org/10.1177/23969873211026998.
[85] SHOAMANESH A，PATRICE LINDSAY M，CASTELLUCCI L A，et al. Canadian stroke best practice recommendations：management of spontaneous intracerebral hemorrhage，7th edition update 2020[J]. Int J Stroke，2021，16（3）：321-341.
[86] GREENBERG S M，ZIAI W C，CORDONNIER C，et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage：a guideline from the American Heart
Association/American Stroke Association[J/OL]. Stroke，2022，53（7）：e282-e361[2023-12-20]. https://doi.org/10.1161/str.0000000000000407.
[87] MA L，HU X，SONG L L，et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial（INTERACT3）：an international，stepped wedge cluster randomised controlled trial[J]. Lancet，2023，402（10395）：27-40.
[88] ZIAI W C，BOWER M，HANLEY D F. Acute spontaneous intracerebral haemorrhage：does a care bundle approach work?[J]. Lancet，2023，402（10395）：2-3.